Related Experiment Video
Updated: Dec 17, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Prevalence of poor lipid control in patients with premature coronary artery disease
Martínez-Sánchez Froylan D1, Jorge-Galarza Esteban1, Posadas-Romero Carlos1
1Department of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano 1, Sección XVI, C.P. 14080, Tlalpan, Mexico City, Mexico.
Insights
Lipid control is poor in premature coronary artery disease patients, with low adherence and obesity being key factors. Achieving lipid goals requires better treatment adherence and more aggressive statin therapy for these high-risk individuals.
Area of Science:
- Cardiology
- Lipidology
- Preventive Medicine
Background:
- Lipid management goals are increasingly stringent for high-risk patients.
- Premature coronary artery disease (CAD) patients often require comprehensive lipid control.
- No prior studies have assessed composite lipid goal achievement in premature CAD.
Purpose of the Study:
- To evaluate lipid control rates in premature CAD patients.
- To identify factors associated with failure to achieve composite lipid goals.
Main Methods:
- 1196 patients with premature CAD (men <55, women <65 years) were analyzed.
- Lipid control was assessed using American Heart Association/American College of Cardiology (non-strict) and American Association of Clinical Endocrinologists (strict) criteria.
- Data on sociodemographics, diet, and clinical factors were collected.
Main Results:
- Lipid control was achieved in only 23.0% (non-strict) and 8.9% (strict) of patients.
- 46.5% (non-strict) and 62.8% (strict) failed to meet any lipid goal.
- Poor control was linked to treatment adherence <85%, low/moderate-intensity statin use, and obesity.
Conclusions:
- Lipid control is suboptimal in patients with premature CAD.
- Low treatment adherence, underutilization of high-intensity statins, and obesity are independently associated with poor lipid control.
- Enhanced preventive strategies and aggressive pharmacological interventions are crucial for reducing premature CAD burden.
Background And Aims:
Lipid goals have become more stringent in high risk patients. However, no studies have analyzed lipid control defined as the composite achievement of goals in low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (Non-HDL-C) and apolipoproteinB-100 (ApoB-100), in patients with premature coronary artery disease (CAD). We aimed to analyze lipid control rates, and the associated factors with its poor achievement in patients with premature CAD.
Methods And Results:
The study included 1196 patients with CAD diagnosed before 55 and 65 years old in men and women, respectively. The American Heart Association/American College of Cardiology (non-strict) and the American Association of Clinical Endocrinologists (strict) criteria were used to analyze lipid control rates. Sociodemographic, dietary-healthy and clinical characteristics of the patients were collected. Participants were 54 ± 8 years old, 19.7% were women, and median CAD evolution was 2.4 years. Non-strict and strict lipid control was achieved in 23.0% and 8.9% of the patients, respectively. Moreover, 46.5% and 62.8% of the patients did not achieve any lipid goal using both criteria. Sociodemographic data were not different among patients who achieved or not lipid control. Treatment adherence<85%, prescription of low- and moderate-intensity statins, and obesity were consistently associated with poor lipid control.
Conclusions:
Lipid control is suboptimal in patients with premature CAD. Low lipid-lowering treatment adherence, low prescription of high-intensity statins, and obesity were independently associated with poor lipid control. Novel preventive programs and more aggressive pharmacological intervention should be implemented in order to reduce the burden of premature CAD.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease I: Introduction
Atherosclerosis III: Management
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease V: Interprofessional Care